Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Avid Bioservices Inc chart...

About the Company

avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.

CEO

Richard Hancock

Exchange

NASDAQ

Website

http://avidbio.com/

$13M

Total Revenue

307

Employees

$398M

Market Capitalization

-34.58

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CDMO News

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

1d ago, source:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of ...

The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

5d ago, source: Business Wire

The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ...

Avid Bioservices

4d ago, source: Forbes

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and ...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

4d ago, source: TMCnet

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices, Inc. ("Avid" or the "Company" ...

Avid Bioservices sinks 32% after Q3 Report

12d ago, source: Orange County Business Journal

Shares of Avid Bioservices Inc. (Nasdaq: CDMO) fell about 32% in after-hours trading after the company reported fiscal ...

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes

11d ago, source:

The 2029 Notes will represent senior unsecured obligations of the company and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, ...

Avid Bioservices Inc (CDMO) Releases Preliminary Q3 Financial Results

8d ago, source:

Backlog: The company discussed its backlog, indicating future revenue potential.

Avid Bioservices, Inc.

2mon ago, source: CNN

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology ...

Avid Bioservices Inc TEHN

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Avid Bioservices Announces Proposed Private Placement of Convertible Notes

12d ago, source: Business Insider

TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...